---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Liver-directed therapies"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Liver-directed therapies. Topics: Guideline recommendations for surgical resection, thermal ablation, and stereotactic radiotherapy; Guideline recommendations for regional hepatic perfusion; Liver-directed options listed in the NCCN guidelines, as summarized by the FOCUS investigators; Melphalan percutaneous hepatic perfusion: single-arm phase 3 FOCUS study, treated population of 91 participants; 16 further topics. 20 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/liver-directed-therapies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Liver-directed therapies

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Liver-directed Therapies

<a id="topic-2.2.2.1.3-1"></a>

### Guideline recommendations for surgical resection, thermal ablation, and stereotactic radiotherapy

> “Patients with oligometastatic UM with metastases confined to the liver can be considered for surgical resection and/or local liver-directed therapies (thermal ablation with radiofrequency, cryoablation or microwave ablation) [IV, B].”
> “SRT could be an alternative in patients not eligible for surgery or thermal ablation [IV, B].”
> “Preoperative MRI can be recommended as well as laparoscopy before or at the time of planned resection [IV, B].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.3-2"></a>

### Guideline recommendations for regional hepatic perfusion

> “Patients with multifocal liver metastases confined to the liver should be considered for regional liver-directed therapies (PHP or IHP) [II, B].”
> “Patients with liver-dominant disease and a good general condition can be considered for regional treatment at any line of metastatic recurrence.”
> “The melphalan for Injection/Hepatic Delivery System, recently approved by the Food and Drug Administration (FDA), may be considered an option in patients with HLA-A∗02:01-negative UMLMs and limited tumour burden.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.3-3"></a>

### Liver-directed options listed in the NCCN guidelines, as summarized by the FOCUS investigators

> “the National Comprehensive Cancer Network guidelines recommend for those patients, among other options, liver-directed therapies, including transarterial chemoembolization (TACE), radioembolization or immunoembolization, and thermal ablation, as well as locoregional perfusion procedures delivering high-dose chemotherapeutic agents, namely, intrahepatic perfusion (IHP), a surgical procedure, and percutaneous hepatic perfusion (PHP), a minimally invasive procedure.”

Source: [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/)

<a id="topic-2.2.2.1.3-4"></a>

### Melphalan percutaneous hepatic perfusion: single-arm phase 3 FOCUS study, treated population of 91 participants

> “The multicenter, open-label, phase 3 FOCUS study was designed to evaluate the efficacy and safety of melphalan/HDS in patients with unresectable mUM.”
> “Due to slow enrollment, with patient reluctance to receive BAC treatment, the study design was amended to a single-arm study, after which all eligible patients received treatment with melphalan/HDS.”
> “Eligible patients with mUM received treatment with melphalan (3.0 mg/kg ideal body weight) once every 6 to 8 weeks for a maximum of six cycles.”
> “The study enrolled 102 patients with mUM.”
> “In the treated population ( n = 91), the ORR was 36.3 % (95 % confidence interval [CI], 26.44–47.01), including 7.7 % of patients with a complete response.”
> “The median DOR was 14 months, and the median OS was 20.5 months, with an OS of 80 % at 1 year.”
> “The median PFS was 9 months, with a PFS of 65 % at 6 months.”

Source: [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/)

<a id="topic-2.2.2.1.3-5"></a>

### Selection criteria in the FOCUS study: liver involvement up to 50 percent

> “The study population included male and female patients 18 years of age or older with histologically verified mUM to the liver; liver tumor involvement of up to 50 %; at least one measurable liver lesion as assessed by contrast-enhanced computed tomography (CT) scans of the chest, abdomen, and pelvis as well as contrast-enhanced MRI of the liver (and brain and bone scans when indicated)”
> “The eligibility criteria were designed to minimize the risks associated with the procedure (e.g., exclusion of patients with moderate or severe liver cirrhosis, portal hypertension, or New York Heart Association [NYHA] II–IV status).”

Source: [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/)

<a id="topic-2.2.2.1.3-6"></a>

### Melphalan percutaneous hepatic perfusion versus best alternative care: randomized portion of FOCUS, 85 participants

> “The multicenter, open-label, Phase 3 FOCUS study was designed to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable mUM in comparison to best alternative care (BAC).”
> “Due to slow enrollment and patient reluctance to receive BAC treatment, the study design was amended to a single-arm Melphalan/HDS study, and all efficacy analyses of the randomized study were treated as exploratory.”
> “The study enrolled 85 patients.”
> “Eligible patients were randomized to receive Melphalan/HDS ( n = 43) or BAC ( n = 42), and 72 patients received study treatment (Melphalan/HDS [ n = 40]; BAC [ n = 32]).”
> “Exploratory analyses of efficacy endpoints showed numerical differences consistently favoring the Melphalan/HDS arm versus BAC (median overall survival: 18.5 vs. 14.5 months; median progression-free survival: 9.1 vs. 3.3 months; objective response rate: 27.5% vs. 9.4%; and disease control rate: 80.0% vs. 46.9%).”
> “Serious adverse events (SAEs) occurred in 51.2% of Melphalan/HDS and in 21.9% of BAC patients.”

Source: [Zager et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12130151/)

<a id="topic-2.2.2.1.3-7"></a>

### Melphalan percutaneous hepatic perfusion versus best available care: earlier randomized phase 3 trial of 93 participants

> “A total of 93 patients were randomized to PHP-Mel ( n = 44) or BAC ( n = 49).”
> “This randomized, phase III study demonstrated the efficacy of the PHP-Mel procedure.”
> “hPFS was 7.0 months for PHP-Mel and 1.6 months for BAC ( p < 0.0001), while oPFS was 5.4 months for PHP-Mel and 1.6 months for BAC ( p < 0.0001).”
> “Median OS was not significantly different (PHP-Mel 10.6 months vs. BAC 10.0 months), likely due to crossover to PHP-Mel treatment (57.1 %) from the BAC arm, and the hOR was 36.4 % for PHP-Mel and 2.0 % for BAC ( p < 0.001).”

Source: [Hughes et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185532/)

<a id="topic-2.2.2.1.3-8"></a>

### Isolated hepatic perfusion versus best alternative care: randomized phase 3 trial, response and progression-free survival

> “In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group).”
> “Patients with histologically or cytologically confirmed liver metastases from uveal melanoma were eligible if they had measurable disease according to RECIST version 1.1 criteria, had received no previous therapy for melanoma metastases (ie, first-line therapy), and had no evidence of extrahepatic disease by positron emission tomography-computed tomography (CT).”
> “Ninety-three patients were randomly assigned, and 87 patients were assigned to either IHP (n = 43) or a control group receiving the investigator's choice of treatment (n = 44).”
> “In an intention-to-treat analysis, the overall response rates (ORRs) were 40% versus 4.5% in the IHP and control groups, respectively ( P < .0001).”
> “The median PFS was 7.4 months versus 3.3 months ( P < .0001), with a hazard ratio of 0.21 (95% CI, 0.12 to 0.36), and the median hPFS was 9.1 months versus 3.3 months ( P < .0001), both favoring the IHP arm.”
> “There was one treatment-related death in the IHP group.”

Source: [Olofsson Bagge et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10414734/)

<a id="topic-2.2.2.1.3-9"></a>

### Isolated hepatic perfusion versus best alternative care: SCANDIUM final overall survival

> “In this phase III randomized controlled multicenter trial (the SCANDIUM trial), patients with previously untreated isolated uveal melanoma liver metastases were included between 2013 and 2021, with at least 24 months of follow-up.”
> “The primary endpoint was the 24-month OS rate, with the hypothesis of a treatment effect leading to a 50% OS rate in the IHP group compared to 20% in the control group.”
> “The 24-month OS rate was 46.5% in the IHP group versus 29.5% in the control group ( P =0.12).”
> “The median OS was 21.7 months versus 17.6 months, with a hazard ratio of 0.64 (95% CI, 0.37–1.10).”

Source: [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)

<a id="topic-2.2.2.1.3-10"></a>

### Percutaneous hepatic perfusion with or without ipilimumab plus nivolumab: single-centre randomized phase 2 trial

> “In this investigator-initiated, single-centre, open-label, randomised, phase 2 trial, adults aged 18-80 years with unresectable liver-only or liver-dominant metastatic uveal melanoma, WHO performance status 0-1, and with no previous systemic therapy were randomly assigned (1:1) to receive percutaneous hepatic perfusion alone (perfusion group) or percutaneous hepatic perfusion combined with ipilimumab plus nivolumab (combination group).”
> “1-year progression-free survival was 54·7% (95% CI 36·8-69·5) with combination therapy versus 15·8% (5·8-30·1) with perfusion alone (adjusted hazard ratio 0·34 [95% CI 0·19-0·60]; p=0·0002).”
> “Grade 3-4 treatment-related adverse events occurred in 31 (82%) of 38 patients with combination therapy compared to 15 (41%) of 37 patients with perfusion alone, due to both a higher incidence of severe perfusion-related events and immunotherapy-related adverse events.”
> “One treatment-related death (due to triple M syndrome) occurred in the combination group.”

Source: [van den Hoek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41785896/)

<a id="topic-2.2.2.1.3-11"></a>

### Surgical resection of liver metastases: outcomes and selection criteria in the guideline

> “Retrospective cohorts have reported a median OS of 14-29 months after surgery of UMLMs.”
> “Median progression-free survival (PFS) and OS after resection with curative intent are 12 months and 26 months, respectively, with reported 5-year survival rates of ∼35% in highly selected patients.”
> “Surgery with curative intent (R0 resection) is the treatment of choice when the disease-free interval from primary tumour diagnosis to liver metastases is >24 months, and the number of metastases is ≤4 in the absence of miliary disease.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.3-12"></a>

### Surgical resection of liver metastases: single-institution series of 255 resected participants

> “To review the evolving surgical management of this challenging condition at a single institution over a 16-year period.”
> “255 patients underwent surgical resection.”
> “The median overall postoperative survival was 14 months, but increased to 27 months when R0 resection was possible.”
> “With multivariate analysis, four variables were found to independently correlate with prolonged survival: an interval from primary tumour diagnosis to liver metastases >24 months, comprehensiveness of surgical resection (R0), number of metastases resected (< or = 4) and absence of miliary disease.”

Source: [Mariani et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19329272/)

<a id="topic-2.2.2.1.3-13"></a>

### Surgical resection of metastases in highly selected patients

> “Surgical resection of metastases from ocular melanoma has been reported in case series of highly selected patients with occasional favorable outcomes.”
> “However, the favorable outcomes may be the result of strong patient-selection factors, and the role of resection in this setting is unclear.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.2.1.3-14"></a>

### Thermal ablation compared with resection

> “Compared with liver resection, cryoablation, microwave or radiofrequency ablation is associated with lower complication rates, lower costs, shorter hospital stays and faster patient recovery.”
> “A retrospective study comparing resection and percutaneous ablation in 57 and 15 patients, respectively, found no difference in median OS (27 months versus 28 months).”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.3-15"></a>

### Hepatic arterial infusion, transarterial chemoembolization, and radioembolization: guideline summary

> “In hepatic arterial infusion (HAI), also known as intra-arterial or transarterial ChT, ChT is administered through a catheter placed in the hepatic artery.”
> “Many cytotoxic agents have been tested, with fotemustine being the most active.”
> “Studies investigating TACE in patients with UMLMs are limited to retrospective and small phase II trials and vary widely in the type of cytotoxic drugs and embolic agents used, the number of procedures per patient and patient selection criteria.”
> “The larger studies reported ORRs of 14%-46%, median PFS of 3-8 months and median OS of 5-29 months.”
> “In transarterial radioembolisation (TARE), microspheres labelled with yttrium-90 or holmium-166 have been studied in retrospective and small prospective series; median PFS was 5.4 months and median OS was 12.3 months.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.3-16"></a>

### Immunoembolization with GM-CSF versus bland embolization: randomized phase 2 trial of 52 participants with liver-only metastases

> “To investigate the effects of immunoembolization with granulocyte–macrophage colony-stimulating factor (GM-CSF) in patients with uveal melanoma (UM) with liver-only metastasis.”
> “In this double-blind phase II clinical trial, patients were randomized to undergo immunoembolization or bland embolization (BE).”
> “Fifty-two patients (immunoembolization, n = 25; BE, n = 27) were enrolled.”
> “There were five partial responses in the immunoembolization group (ORR, 21.2%; 90% confidence interval [CI], 10.3%–30.5%) and three in the BE group (ORR, 16.7%; 90% CI, 6.3%–26.9%).”
> “OS times were 21.5 months (95% CI, 18.5–24.8 mo) with immunoembolization and 17.2 months (95% CI, 11.9–22.4 mo) with BE.”

Source: [Valsecchi et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4417549/)

<a id="topic-2.2.2.1.3-17"></a>

### Yttrium-90 radioembolization: prospective phase 2 trial

> “In a prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastases, treatment-naïve participants (n = 24) achieved median overall survival of 18.5 months with a 1-year survival of approximately 61%.”
> “Participants treated with radioembolization in whom prior immunoembolization treatment failed (n = 23) achieved median overall survival of 19.2 months with a 1-year survival of approximately 70%.”

Source: [Gonsalves et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6776232/)

<a id="topic-2.2.2.1.3-18"></a>

### Survival with liver-directed treatment in an individual-patient meta-analysis of 29 trials

> “Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016.”
> “Patients treated with liver directed treatments had statistically significant longer PFS and OS.”

Source: [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)

<a id="topic-2.2.2.1.3-19"></a>

### Pooled overall survival by treatment modality compared with conventional chemotherapy

> “Pooled OS reported after isolated hepatic perfusion [median OS: 1.34 years; hazard ratio (HR): 0.92, 95% confidence interval (CI): 0.87–0.97, P = 0.0040], immunoembolization (median OS: 1.63; HR: 0.97, 95% CI: 0.95–1.00, P = 0.0080), and surgery (median OS: 1.43; HR: 0.94, 95% CI: 0.92–0.96, P < 0.0001) was longer, and after checkpoint inhibitor shorter (median OS: 0.59; HR: 1.13, 95% CI: 1.06–1.20, P < 0.0001) than after CHT (median OS: 0.91 years), but subject to identifiable confounding factors.”

Source: [Rantala et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6887637/)

<a id="topic-2.2.2.1.3-20"></a>

### Systematic review of liver-directed therapy: 55 studies of 2446 participants

> “55 studies were included in the study, with 2446 patients treated overall.”
> “Both surgery and liver-directed treatments were shown to have benefit in selected patients.”
> “Substantial variability in patient selection and study design makes comparison of data and formulation of recommendations challenging.”

Source: [Rowcroft et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31791894/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
